94088-85-4

94088-85-4 structure
94088-85-4 structure

Name dicalcium,(5R,5aR,6S,6aR,7S,10aS)-9-[amino(oxido)methylidene]-7-(dimethylamino)-10a-hydroxy-5-methyl-8,10,11-trioxo-5a,6,6a,7-tetrahydro-5H-tetracene-1,6,12-triolate
Synonyms DOXYCYCLINE CALCIUM
Doxycycline calcium (internal use)
EINECS 302-088-9
Vibramycin calcium
2-Naphthacenecarboxamide,4-(dimethylamino)-1,4,4a,5,5a,6,11,12a-octahydro-3,5,10,12,12a-pentahydroxy-6-methyl-1,11-dioxo-,calcium salt (1:2),(4S-(4alpha,4aalpha,5alpha,5aalpha,6alpha,12aalpha))
Doxycycline calcium [USAN]
Doxycycline calcium [USAN:USP]
C22H24N2O8.2Ca
Description Doxycycline calcium, an antibiotic, is an orally active and broad-spectrum metalloproteinase (MMP) inhibitor[1]. Doxycycline calcium shows antibacterial activity and anti-cancer cell proliferation activity[1][2][3][4][5].
Related Catalog
In Vitro Doxycycline calcium (0.01-10 µg/mL, 4 d) affects growth of glioma cells only under high concentrations[2]. Doxycycline calcium (0.01-10 µg/mL, 24 h) decreases MT-CO1 protein content with concentrations of 1 µg/mL and higher in SVG cells[2]. Doxycycline calcium (100 ng/mL, 1 µg/mL; 24 h) reduces proliferation of human cell lines[4]. Doxycycline calcium (0-250 μM, 72 h) inhibits cell viability of breast cancer cells [5]. Cell Viability Assay[2] Cell Line: LNT-229, G55, and U343 glioma cells Concentration: 0.01, 0.1, 1 or 10 µg/mL Incubation Time: 4 days Result: Affected growth of glioma cells only under high concentration (10 µg/mL). Cell Viability Assay[2] Cell Line: SVG cells Concentration: 0.01, 0.1, 1 or 10 µg/mL Incubation Time: 24 hours Result: Decreaseed MT-CO1 protein content with concentrations of 1 µg/mL and higher. Cell Proliferation Assay[4] Cell Line: MCF 12A, 293T cells Concentration: 100 ng/mL, 1 µg/mL Incubation Time: 96 hours Result: Caused reduced proliferation of MCF 12A and 293T cells at 1 µg/mL. Cell Viability Assay[5] Cell Line: MCF-7, MDA-MB-468 cells Concentration: 0-250 μM Incubation Time: 72 hours Result: Inhibited breast cancer cells in a dose-dependent manner with IC50 values for MCF-7 and MDA-MB-468 of 11.39 μM and 7.13 μM respectively.
In Vivo Doxycycline calcium (oral gavage; 200 or 800 mg/kg; once daily; 3 months) reduces MMP-9 activity in untreated HT mice in a dose-dependent manner[3]. Animal Model: 6-month-old female Heterozygous Col3a1-deficient (HT) mice[3] Dosage: 200 or 800 mg/kg Administration: Oral gavage; 200 or 800 mg/kg; once daily; 3 months Result: Reduced MMP-9 activity in a dose-dependent manner.
References

[1]. Eusebio Manchado, et al. A combinatorial strategy for treating KRAS-mutant lung cancer. Nature. 2016 Jun 30;534(7609):647-51.

[2]. Anna-Luisa Luger, et al. Doxycycline Impairs Mitochondrial Function and Protects Human Glioma Cells from Hypoxia-Induced Cell Death: Implications of Using Tet-Inducible Systems. Int J Mol Sci. 2018 May 17;19(5):1504.

[3]. Wilfried Briest, et al. Doxycycline ameliorates the susceptibility to aortic lesions in a mouse model for the vascular type of Ehlers-Danlos syndrome. J Pharmacol Exp Ther. 2011 Jun;337(3):621-7.

[4]. Ethan Ahler, et al. Doxycycline alters metabolism and proliferation of human cell lines. PLoS One. 2013 May 31;8(5):e64561.

[5]. Le Zhang, et al. Doxycycline inhibits the cancer stem cell phenotype and epithelial-to-mesenchymal transition in breast cancer. Cell Cycle. 2017 Apr 18;16(8):737-745.

Boiling Point 685.2ºC at 760mmHg
Molecular Formula C22H20Ca2N2O8
Molecular Weight 520.55900
Flash Point 368.2ºC
Exact Mass 520.04700
PSA 137.62000
LogP 0.82460